fascin actin-bundling protein 2, retinalGenealiases: RFSN · RP30
Q-omics provides the consensus-scored FSCN2 profile across patient tissues and cancer cell-line models. FSCN2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FSCN2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FSCN2 RNA expression shows 18,718 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FSCN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FSCN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FSCN2 survival associations across molecular data types. FSCN2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FSCN2 RNA expression–survival associations across cancer types. High FSCN2 expression shows unfavorable associations in ACC, UVM and LGG, but favorable associations in SKCM, HNSC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FSCN2 RNA expression.
This table summarizes FSCN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FSCN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FSCN2 shows lower tumor expression in KIRC and LUSC and higher tumor expression in COAD, LIHC, CHOL and STAD. The KIRC box plot shows higher FSCN2 RNA expression in normal versus tumor tissue (log2 FC = −0.676, t-test p < 0.001).
This table shows molecular features associated with FSCN2 in patient tissues and cancer cell lines. In patient samples, FSCN2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FSCN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
